Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More

Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.

One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.

Here they are – with more opportunities – in our latest Money Morning best stocks to buy list:

Money Morning's Best Stocks to Buy Now

• Tech companies have to remain innovative to succeed. Otherwise, they get rusty. Money Morning's Defense & Tech Specialist Michael A. Robinson found a trio of high-tech "rust" companies that have stayed with old-line businesses or antiquated management – until now. Now this group is modernizing operations to increase sales – and share-price gains. Involved in Big Data, clouding computing, and wearable tech, the three will handsomely reward investors.

• One strategy to use when searching for the most lucrative biopharma stocks to buy is to find companies with promising drug pipelines. Many of these drugs are used to treat rare diseases and come with hefty price tags – which translate to big profits. Money Morning's Robinson zeroed in a newly public company, already a hot biopharma stock, that's poised to reward investors in 2014 thanks to a healthy pipeline of promising treatments.

• If there was a poster child for momentum stocks, this company would be it. It's up some 34% year to date and 269% over the last 12 months. Now it's taking a hit. Despite beating Wall Street's estimates, forward guidance (while upbeat) was a bit sketchy. Nonetheless, its innovative business model strategy should drive the stock higher for years. Money Morning Chief Investment Strategist Keith Fitz-Gerald said the stock has the potential to hit $1,000 over the next decade.